11:00 AM SIGN-IN & LUNCH • 11:30 AM - 1:00 PM

ROOM TBD

CE: Peanut Allergy and the Use of Immunotherapy for Specialty Pharmacists and Payers

The prevalence of peanut allergy has tripled in the past decade, and it is now estimated to affect as many as 1 million US children and adolescents. The management of this allergy is lifelong—just 20% of children are expected to outgrow their peanut allergy—and total direct medical costs per child with a peanut allergy are estimated to be more than $4 billion. With no known cure, accidental exposure to a peanut allergen and incidental anaphylactic reactions can be life-threatening for patients, and such emergencies result in higher health care expenditures. Clinical trials have sought to improve sensitivity thresholds for patients, and the recent approval of peanut oral immunotherapy presents an urgent need for specialty pharmacists and payers to understand the complexities of peanut allergy to effectively integrate this novel therapy into the current treatment paradigm. The crucial role of the specialty pharmacist’s involvement in dispensing treatments for patients with peanut allergy and managing and monitoring adverse effects of therapy will be discussed.

Speakers

Christina Ciaccio

Micaila Ruiz

Asembia

200 Park Avenue, Suite 300 
Florham Park, NJ 07932

973.564.8004

asembia.com

info@asembiasummit.com

SIGN UP FOR SUMMIT UPDATES

Asembia's Specialty Pharmacy Summit is a PRIVATE EVENT. Asembia reserves the right to deny registration and refuse access at our absolute and sole discretion for any reason whatsoever.

© 2020 Asembia Specialty Pharmacy Summit, LLC. All rights reserved.

CONNECT WITH US

  • Asembia LinkedIn
  • Asembia Twitter
  • Asembia Instagram
  • Asembia Facebook
  • Asembia Videos
  • Asembia Photos
2021Summit_Logo_White.png